No profile data available.
MaxCyte, Inc. (MXCT) is a healthcare company in the biological analysis equipment industry, based in Rockville, United States, with about 91 full-time employees.
It reported revenue of $38.63 million for fiscal year 2024, down 6.4% from fiscal year 2023, and net income of -$41.05 million. In Q2 2025 (the quarter ended June 30, 2025) revenue was $8.51 million, down 18.4% from a year before. Its largest business segment, Product, brought in 60% of segment revenue in fiscal year 2025; UNITED STATES was the largest region with 64%. Its market capitalization was $111.46 million as of October 5, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 5, 2026.
, a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally.
MaxCyte reported $38.63 million in revenue for fiscal year 2024, down 6.4% from $41.29 million in fiscal year 2023. In Q2 2025 revenue was $8.51 million.
Product, with $18.69 million or 60% of segment revenue in fiscal year 2025. Next: License (40%).
UNITED STATES: 64% of revenue by region in fiscal year 2025, followed by Non-US (36%).
$111.46 million as of October 5, 2026.
Listed companies of a similar size in the same industry (biological analysis equipment) include Alpha Teknova, Inc. (TKNO), Quanterix Corporation (QTRX), Seer, Inc. (SEER), INmune Bio, Inc. (INMB).